U.S. markets open in 7 hours 28 minutes

Cue Health Inc. (HLTH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.72-0.74 (-6.46%)
At close: 04:00PM EST
10.77 +0.05 (+0.47%)
After hours: 06:37PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close11.46
Bid0.00 x 800
Ask0.00 x 3000
Day's Range10.69 - 11.41
52 Week Range8.53 - 22.55
Avg. Volume1,144,452
Market Cap1.569B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-24% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HLTH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cue Health Inc.
    QDEL: Raising target price to $154.00QUIDEL CORP has an Investment Rating of HOLD; a target price of $154.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • PR Newswire

    Cue Health Receives Singapore HSA Authorization for its Molecular COVID-19 Test for Self-Testing

    Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore. The Cue COVID-19 Test is the first natively digital molecular diagnostic product ever authorized for consumer home use in Singapore. Cue's partnership with Omnicell Pte Ltd allows Cue to immediately begin supporting public sector use of the Cue COVID-19 T

  • PR Newswire

    Cue Health Confirms COVID-19 Tests Can Detect Omicron Variant

    Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron. Using information from the GISAID database, Cue has determined its COVID-19 tests, which uses molecular (NAAT) technology, can detect the Omicron variant. Specifically, Cue found that 99.2% of the available 127 published sequences are a perfect match to the primers used in the Company's tests.

  • PR Newswire

    Helix and Cue Health Collaborate to Provide Individuals with Access to their COVID-19 Variant Sequencing Information

    Helix, a leading genomics company that provides nationwide viral surveillance of respiratory disease, and Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, announced a new collaboration today to provide individuals who test positive on Cue's at-home molecular COVID-19 test the opportunity to learn which variant they have contracted as part of a broader research study on the SARS-CoV-2 virus.